X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CAR-T cells and bispecific antibodies targeting this protein biomarker. The findings of this work will create and evaluate new promising tools for recruiting and activating the patient’s own immune system to track and destroy Ewing sarcoma tumors.
Lead Product(s): Antibody,CAR T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: CancerVAX
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
ARD-101 (denatonium acetate) is a first-in-class oral substantially gut-restricted with minimal systemic exposure yet conveys systemic effects via activation of GLP-1, GLP-2, and which show positive impact on hunger scores in general obesity and Prader-Willi Syndrome.
Lead Product(s): Denatonium Acetate
Therapeutic Area: Genetic Disease Product Name: ARD-101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Aardvark Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
MYT-109 improves mitochondrial functions and rescues lethality in animal models of Leigh’s Syndrome. It’s a prodrug, using a proprietary technology, with improved PK compared to other fumarate based drugs.
Lead Product(s): Monomethyl Fumarate Prodrug
Therapeutic Area: Rare Diseases and Disorders Product Name: MYT-109
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Myto Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
VPO-227 is a small-molecule with a novel mechanism of action which blocks the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel,in development for the treatment of secretory disorders, including cholera.
Lead Product(s): VPO-227
Therapeutic Area: Infections and Infectious Diseases Product Name: VPO-227
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Vanda Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
Initiation of the Phase 1/2a trial represents the first-in-human clinical study investigating a dual chimeric antigen receptor (duoCAR)-T cell therapy for the treatment of HIV.
Lead Product(s): LVgp120duoCAR-T cells,Cyclophosphamide
Therapeutic Area: Infections and Infectious Diseases Product Name: LVgp120duoCAR-T cells
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Caring Cross
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.
Lead Product(s): TRE-515
Therapeutic Area: Neurology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Trethera
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The enrollment progress for the Phase II part 2 clinical study of ABV-1505 (Radix Polygalae Extract). Since the first subject began treatment on May 10, 2022, 13 additional subjects have been enrolled in the study from a total of 23 subjects screened.
Lead Product(s): Radix Polygalae Extract
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1505
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ABVC BioPharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
PDC-1421, active ingredient of ABV-1505 and ABV-1504 , a plant based drug targeting ADHD symptoms in adults inhibit norepinephrine transporter (NET) for major depressive disorder.
Lead Product(s): Radix Polygalae Extract
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1505
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ABVC BioPharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
High-throughput platform will enable the Olson Lab to quickly examine the vast psychoplastogen chemical space in the search for new neurotherapeutics. This partnership will help to understand the complex chemical and pharmacological space occupied by psychoplastogens
Lead Product(s): Psychoplastogen
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: NemaLife
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 19, 2022
Details:
AVR-RD-04 is an investigational, lentiviral-based gene therapy designed to potentially halt or reverse the progression of cystinosis with a single dose of the patient’s own hematopoietic stem cells.
Lead Product(s): AVR-RD-04
Therapeutic Area: Genetic Disease Product Name: AVR-RD-04
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Avrobio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
